SCYNEXIS receives $5M third tranche from Hercules/SVB Term Loan after CANDLE milestone

SCYNEXIS INC

On March 9, 2022, SCYNEXIS drew $5M under its existing $60M Term Loan with Hercules/SVB.
The tranche was triggered by positive Phase 3 CANDLE study results for ibrexafungerp.
Prior draws: $20M at closing (May 2021), $10M on FDA approval (June 2021).
Total drawn now $35M; remaining tranches subject to conditions.
Loan facility provided by Hercules Capital and Silicon Valley Bank.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.